Table 1 Summary results for newly identified risk loci

From: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility

 

Nearest genea

Risk allele (frequency)

 

Discovery GWAS meta-analysis

UK Replication 1

UK Replication 2

Meta-analysis

   

Position (hg19, bp)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

I2 (%)

P het

3q28, rs4459895

LPP

A (0.20)

187954414

          

 cHL

   

4.16 × 10−10

1.27 (1.18–1.36)

6.85 × 10−9

1.44 (1.27–1.63)

0.02

1.26 (1.04–1.52)

4.45 × 10−18

1.30 (1.23–1.38)

13

0.33

 NSHL

   

9.16 × 10−9

1.37 (1.23–1.53)

1.37 × 10−8

1.43 (1.26–1.62)

0.04

1.30 (1.02–1.66)

9.43 × 10−17

1.39 (1.28–1.50)

0

0.93

 MCHL

   

0.92

1.04 (0.91–1.19)

  

0.98

1.00 (0.68–1.47)

0.55

1.04 (0.92–1.19)

0

0.82

6q22.33, rs9482849

PTPRK

C (0.17)

128288536

          

 cHL

   

5.02 × 10−8

1.24 (1.15–1.35)

0.13

1.11 (0.97–1.27)

0.13

1.17 (0.95–1.43)

1.52 × 10−8

1.20 (1.13–1.28)

3

0.39

 NSHL

   

2.91 × 10−6

1.32 (1.17–1.48)

0.17

1.10 (0.96–1.25)

0.20

1.19 (0.91–1.54)

4.13 × 10−6

1.21 (1.12–1.33)

10

0.35

 MCHL

   

0.17

1.11 (0.96–1.28)

  

0.78

1.06 (0.70–1.61)

0.16

1.10 (0.96–1.26)

0

0.97

6q23.3, rs6928977

AHI1

G (0.57)

135626348

          

 cHL

   

1.66 × 10−8

1.18 (1.12–1.26)

0.01

1.14 (1.03–1.26)

0.05

1.16 (1.00–1.34)

1.24 × 10−10

1.17 (1.12–1.23)

0

0.85

 NSHL

   

9.34 × 10−10

1.31 (1.20–1.42)

0.03

1.12 (1.01–1.24)

0.01

1.30 (1.06–1.58)

4.62 × 10−11

1.23 (1.16–1.31)

26

0.25

 MCHL

   

0.24

1.06 (0.96–1.18)

  

0.69

1.06 (0.79–1.42)

0.22

1.06 (0.96–1.17)

0

0.22

10p14, rs3781093

GATA3

T (0.88)

8101927

          

 cHL

   

4.89 × 10−12

1.35 (1.23–1.47)

4.00 × 10−4

1.32 (1.25–1.44)

0.11

1.21 (0.96–1.52)

4.91 × 10−12

1.28 (1.19–1.37)

64

0.01

 NSHL

   

9.16 × 10−12

1.53 (1.36–1.75)

2.00 × 10−4

1.44 (1.31–1.61)

0.64

0.92 (0.68–1.26)

9.49 × 10−13

1.39 (1.28–1.53)

61

0.06

 MCHL

   

0.03

1.18 (1.02–1.36)

  

0.05

1.56 (1.02–2.40)

0.16

0.91 (0.79–1.04)

73

0.03

13q34, rs112998813

UPF3A

C (0.08)

115059729

          

 cHL

   

3.63 × 10−3

1.19 (1.06–1.33)

0.03

1.23 (1.03–1.47)

0.43

1.12 (0.84–1.50)

2.70 × 10−4

1.19 (1.08–1.30)

13

0.32

 NSHL

   

8.43 × 10−8

1.58 (1.34–1.88)

0.03

1.22 (1.02–1.47)

0.28

1.23 (0.85–1.78)

4.58 × 10−8

1.39 (1.23–1.56)

27

0.24

 MCHL

   

0.92

0.99 (0.80–1.22)

  

0.27

1.35 (0.80–2.23)

0.75

1.03 (0.85–1.25)

0

0.56

16p13.13, rs34972832

CLEC16A

A (0.18)

11198938

          

 cHL

   

1.45 × 10−4

1.15 (1.07–1.23)

6.34 × 10−3

1.18 (1.05–1.34)

0.10

1.17 (0.97–1.42)

8.03 × 10−7

1.16 (1.09–1.23)

6

0.37

 NSHL

   

7.47 × 10−7

1.24 (1.15–1.34)

6.53 × 10−3

1.30 (1.17–1.45)

0.28

1.15 (0.89–1.50)

2.12 × 10−8

1.24 (1.15–1.34)

37

0.18

 MCHL

   

0.65

0.97 (0.85–1.11)

  

0.91

1.02 (0.69–1.52)

0.70

0.98 (0.86–1.10)

0

0.94

  1. The risk allele is the allele corresponding to the estimated odds ratio. Frequency of the risk allele is from the CEU population from 1000 Genomes Project
  2. cHL classical Hodgkin lymphoma, NSHL nodular sclerosis Hodgkin lymphoma, MCHL mixed cellularity Hodgkin lymphoma, bp base pair, OR odds ratio, CI confidence interval, I2 proportion of the total variation due to heterogeneity
  3. I2 value ≥ 75% is considered to be characteristic of large heterogeneity
  4. aNearest gene may not be the functional gene